

WATSON PHARMACEUTICALS INC
Form SC 13G
February 12, 2003

=====
IRS # 953872914
CIK # 0000884629

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934*

WATSON PHARMACEUTICALS

(Name of Issuer)

Common Stock

(Title of Class of Securities)

942683103

(CUSIP Number)

December 31, 2002

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: WATSON PHARMACEUTICALS INC - Form SC 13G

Page 1 of 4

CUSIP NO. 942683103

Barrow, Hanley, Mewhinney & Strauss

NAMES OF REPORTING PERSONS.

1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

752403190

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)
(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4 a Nevada Corporation

SOLE VOTING POWER

5
NUMBER OF
SHARES

SHARED VOTING POWER

6
BENEFICIALLY
OWNED BY

SOLE DISPOSITIVE POWER

7
EACH
REPORTING
PERSON

SHARED DISPOSITIVE POWER

8
WITH

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)

10

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

11

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12

1A

=====
Item 1

- (a) Name of Issuer Watson Pharmaceuticals
- (b) Address of Issuer's Principal Executive Offices
- 311 Bonnie Circle
Corona, Ca. 92880

Item 2

- (a) Name of Person Filing Barrow, Hanley, Mewhinney & Strauss
- (b) Address of Principal Business Office or, if none, Residence
- One McKinney Plaza
3232 McKinney Avenue
15th Floor
Dallas, TX 75204-2429
- (c) Citizenship a Nevada Corporation
- (d) Title of Class of Securities Common Stock
- (e) CUSIP Number 942683103

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b):

The reporting person is an Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940.

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:
- (b) Percent of class:
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote
- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

Instruction. For computations regarding securities which represent a right

Edgar Filing: WATSON PHARMACEUTICALS INC - Form SC 13G

to acquire an underlying security see (S)240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable

Instruction: Dissolution of a group requires a response to this item.

Page 3 of 4

=====
Item 6. Ownership of More than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item, and if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of the employee benefit plan, pension fund or endowment fund is not required.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to (S)240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to (S)240.13d-1(c) or (S)240.13d-1(d), attach an exhibit stating the identity of each member of the group.

Item 9. Notice of Dissolution of a Group

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

Item 10. Certification

By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

Edgar Filing: WATSON PHARMACEUTICALS INC - Form SC 13G

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barrow, Hanley, Mewhinney & Strauss, Inc.

By: /s/ James P. Barrow

Signature

James P. Barrow / President

Name/Title

February 8, 2002

Page 4 of 4